• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2012; 7(7): e39268.
Published online Jul 9, 2012. doi:  10.1371/journal.pone.0039268
PMCID: PMC3392254

RBPJ Is a Novel Target for Rhabdomyosarcoma Therapy

Qiang Wang, Editor

Abstract

The Notch pathway regulates a broad spectrum of cell fate decisions and differentiation processes during fetal and postnatal development. In addition, the Notch pathway plays an important role in controlling tumorigenesis. However, the role of RBPJ, a transcription factor in the Notch pathway, in the development of tumors is largely unknown. In this study, we focused on the role of RBPJ in the pathogenesis of rhabdomyosarcoma (RMS). Our data showed that Notch pathway genes were upregulated and activated in human RMS cell lines and patient samples. Inhibition of the Notch pathway by a γ-secretase inhibitor (GSI) decreased the in vitro proliferation of RMS cells. Knockdown of RBPJ expression by RNAi inhibited the anchorage-independent growth of RMS cells and the growth of xenografts in vivo. Additionally, overexpression of RBPJ promoted the anchorage-independent growth of RMS cells. Further, we revealed that RBPJ regulated the cell cycle in RMS xenograft tumors and decreased proliferation. Our findings suggest that RBPJ regulates the RMS growth, and that the inhibition of RBPJ may be an effective therapeutic approach for patients with RMS.

Introduction

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents [1], [2], [3]. Pediatric RMS can be divided into 2 major subtypes, embryonal RMS (eRMS) and alveolar RMA (aRMS). The cure rates for patients with nonmetastatic RMS have improved significantly from an estimated 25% in 1970 to 75% at present. Prognosis for RMS is dependent on the anatomic site of the primary tumor, age, completeness of resection, presence and the number of metastatic sites, and histological and biological characteristics of the tumor cells [4], [5]. The advances in the understanding of tumor biology may lead to the development of novel clinically relevant therapeutic targets in the near future.

The Notch signaling cascade is highly conserved and plays a crucial role in the self-renewal of stem cells, cell fate determination, epithelial cell polarity, adhesion, cell division, and apoptosis [6], [7], [8]. The mammalian family of Notch receptors consists of 4 members (NOTCH1-4) and the ligand family consists of 5 members (JAGGED 1/2 and DELTA 1/3/4). In the absence of ligand binding, the Notch receptors are inactive. Upon ligand binding, the Notch receptor is cleaved in 2 sequential steps. The cleavage events release the intracellular domain of the Notch receptor (NICD), and the NICD regulates the downstream target genes via the DNA-binding factor, RBPJ/CBF1 [9], [10]. The transcriptional regulator RBPJ is a highly conserved DNA-binding protein that plays a central role in canonical Notch signaling [11].

Recently, alterations in the Notch pathway have been observed in different solid tumors, including breast cancer, ovarian cancer, melanoma, glioblastoma, and lung and pancreatic cancer [12], [13], [14]. In addition, aberrant activation of the Notch-RBPJ pathway is involved in Epstein–Barr virus (EBV) infection [15], [16], T-lymphoblastic leukemia (T-LL), and gliomas [17], [18].

We previously reported that inhibition of the Notch pathway suppressed the growth of osteosarcoma by regulation of cell cycle [19]. In this study, we found that the Notch pathway was also functionally activated in human RMS, and a γ-secretase inhibitor (GSI) X reduced the in vitro proliferation of RMS cells. Moreover, we show that inhibition of RBPJ expression prevents the growth of RMS in vitro and in vivo.

Materials and Methods

Cell Lines

RD and KYM-1 cell lines were obtained from the Health Science Research Resources Bank (HSRRB, Osaka, Japan). RMS-YM cell line was obtained from Riken Bioresource Center (Tsukuba, Japan). HSKMc cell line was purchased from TOYOBO (Osaka, Japan). RD and KYM-1 cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin. RMS-YM cell line was cultured in RPMI 1640 medium supplemented with 10% FBS, 100 µM nonessential amino acids (NEAA), 20 mM HEPES, 100 U/mL penicillin, and 100 µg/mL streptomycin. HSKMc cell line was cultured in skeletal muscle cell growth medium (TOYOBO, Osaka, Japan). All cells were maintained at 37°C in 5% CO2.

Patient Specimens

Human eRMS biopsy specimens were collected from primary lesions before any diagnostic or therapeutic treatment. Human skeletal muscle tissues were collected from patients undergoing operation for scoliosis. The study protocol was approved by the institutional Review Board of Kagoshima University. Informed consent was obtained from all patients.

Real-time PCR Analysis

Real-time PCR analysis was performed as previously described [20]. Total RNA was extracted from cell lines and tissue specimens using miR-Vana RNA isolation kit or TRIzol (Invitrogen, CA, USA) and was reverse transcribed using ReverTra Ace -α- (TOYOBO, Osaka, Japan). cDNA was amplified by real-time PCR using SYBR Green (Life Technologies, NY, USA). Real-time PCR was performed on MiniOpticon™ (Bio-Rad, Tokyo, Japan). The comparative Ct (ΔΔCt) analysis was performed to evaluate the fold change of mRNA expression, using the expression of ACTB as a reference. All PCR reactions were performed in triplicate. All primers were designed. using Primer 3 software. The following primers were used: ACTB, 5′-AGAAAATCTGGCACCACACC-3′ and 5-AGAGGCGTACAGGGATAGCA-3′; NOTCH1, 5′-GTGACTGCTCCCTCAACTTCAAT-3′ and 5′-CTGTCACAGTGGCCGTCACT-3′; NOTCH2, 5′-GTGTCAGAATGGAGGGGTTTG-3′ and 5′-ATTGCGGTTGGCACAGG-3′; NOTCH3, 5′-CAACCCGGTGTACGAGAAGT-3′ and 5′-GAACGCAGTAGCTCCTCTGG-3′; NOTCH4, 5′-CCATTGACACCCAGCTTCTT-3′ and 5-GCTGAACAGAAGTCCCGAAG-3′; JAG1, 5′-CAGATTTCCTTGTTCCCTTGCT-3′ and 5′-CGTTGTTGGTGGTGTTGTCC-3′; DLL1, 5′-CCTACTGCACAGAGCCGATCT-3′ and 5′-GCAGGTGGCTCCATTCTTGC-3′; HES1, 5′-AGGCGGACATTCTGGAAATG-3′ and 5′-CGGTACTTCCCCAGCACACTT-3′; HEY1, 5′-CGAGGTGGAGAAGGAGAGTG-3′ and 5′-CTGGGTACCAGCCTTCTCAG-3′; RBPJ, 5′-CGCATTATTGGATGCAGATG-3′ and 5′-CAGGAAGCGCCATCATTTAT-3′; Cyclin D, 5′-CAGAAGTGCGAGGAGGAGGT-3′, and 5′-CGGATGGAGTTGTCGGTGT-3′; Cyclin E, 5′-CCACACCTGACAAAGAAGATGATGAC-3′ and 5′-GAGCCTCTGGATGGTGCAATAAT-3′; E2F1, 5′-ATGTTTTCCTGTGCCCTGAG-3′ and 5′-ATCTGTGGTGAGGGATGAGG-3′; SKP2, 5′-TGGGAATCTTTTCCTGTCTG-3′ and 5′-GAACACTGAGACAGTATGCC-3′; p21, 5′-GACACCACTGGAGGGTGACT-3′ and 5′-ACAGGTCCACATGGTCTTCC-3′.

Cell Proliferation Assay

Cell proliferation assay was performed as previously described [21]. We seeded 1×103 cells (RD) or 3×103 cells (KYM-1)/100 µL in a 96 -well plate. Next day, the cells were placed in fresh medium containing the indicated concentration of the GSI X (CALBIOCHEM, Basel, Switzerland), GSI XX (CALBIOCHEM, Basel, Switzerland) or DMSO and were cultured for 3–4 days. Cell growth were measured daily by performing WST-1 assay (Roche, Basel, Switzerland).

Plasmid Constructs and Gene Transfer

Control siRNA (S20C-0600) was purchased from B-Bridge International (Cupertino, USA) and RBPJ siRNA (sc-38214) was purchased from Santa Cruz Biotechnology (CA, USA). All siRNA transfection experiments were performed using Lipofectamine RNAiMAX (Invitrogen, CA, USA) transfection reagent according to the manufacturer’s protocol. Control or RBPJ shRNA (KH06319P) were purchased from SuperArray Biosciences (MD, USA). pCMV6-Entry Vector (PS100001) and RBPJ expression vector (RC204791) were purchased from Origene (Maryland, USA). All plasmid transfection experiments were performed using FuGENE6 (Roche, Basal, Switzerland) transfection reagent according to the manufacturer’s protocol. Tranfected cells were selected in 700 µg/mL neomycin or 0.4 ng/µL puromycin. Stable cell lines were then used for colony formation assay and in vivo experiments.

Colony Formation Assay

Colony formation assay was performed as previously described [22]. Cells were suspended in DMEM containing 0.33% soft agar and 5% FBS and then were plated on a 0.5% soft agar layer. Cells were cultured at a density of 2×104 cells per well in 6-well plates. After 2–3 weeks (RBPJ siRNA/RD: 2 weeks, RBPJ/RD: 3 weeks), the number of colonies was counted. Every experiment was performed in triplicate, and all experiments were performed 3 times.

Western Blotting Analysis

Western blotting analysis was performed as previously described [23].

Cells were lysed using NP40 buffer, including 0.5% NP40, 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 3 mM pAPMSF (Wako Chemicals, Kanagawa, Japan), 5 mg/mL aprotinin (Sigma, StLouis, USA), 2 mM sodium orthovanadate (Wako Chemicals, Kanagawa, Japan), and 5 mM EDTA. Lysates were boiled with sodium dodecyl sulfate (SDS) sample buffer, separated by SDS-polyacrylamide gel electrophoresis (PAGE) (Bio-Rad, Tokyo, Japan), and transferred to a polyvinylidene fluoride (PVDF) membrane (Caliper LifeSciences, CA, USA). The membranes were blocked in 5% nonfat dry milk TBST buffer and incubated in primary antibodies diluted in TBST for 1 h at room temperature or overnight at 4°C. Blots were washed using TBST buffer and incubated with horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology) in TBST buffer for 45 min at room temperature. Immunocomplexes were visualized using an enhanced chemiluminescence kit (GE Healthcare, Tokyo, Japan). Primary antibodies were RBPJ (1[ratio]300, ab33065, abcam), PARP (1[ratio]1000, #9542, Cell Signaling) and α-tubulin (1[ratio]1000, DM1A, Sigma-Aldrich).

Animal Studies

Xenograft experiments were performed as previously described [24]. Briefly, control or RBPJ shRNA-transfected RD cells (1×106) were suspended in 100 µL Matrigel (BD, NJ, USA). Cell suspensions were subcutaneously inoculated in 5-week-old nude mice (Japan SLC, Inc). Tumor size was calculated weekly using the formula LW2/2 (with L and W representing the length and width of tumors). Kaplan–Meier analysis was performed using Kaplan 97 software. All animal experiments were performed in compliance with the guidelines and approved by the Animal Science Laboratory, Frontier Science Research Center,Kagoshima University.

Immunohistochemistry

For Ki-67 staining, antigen retrieval was performed using CC1 antigen retrieval buffer (Ventana Medical Systems, Tucson, AZ, U.S.A.) for all sections. Following incubation with the primary antibody against Ki-67 (MIB-1, DAKO, dilution rate at 1[ratio]50), sections were stained on the Ventana automated slide stainer (Benchmark XT) using the Ventana diaminobenzidine detection kit (Ventana Medical Systems). Ki67 immunostainings were scored by counting at least 1000 cells in 5 randomized fields. Every stained nucleus was considered positive, irrespective of intensity.

For detection of apoptotic small bodies, cells were fixed by 4% paraformaldehyde for 20 min, washed in PBST (PBS containing 0.05% Tween20), and then permeabilized in PBS containing 0.2% Triton X-100 for 10 min. After the wash, the cells were treated with PBS containing 10 µg/mL Hoechst 33342 dye (Molecular Probes, Oregon, U.S.A) for 30 min, and then were washed. The apoptotic cells were visualized by fluorescence microscopy (Leica Microsystems, Wild Heerbrugg, Switzerland).

Statistical Analysis

All the data are expressed as mean ± SD. Statistical analysis was performed using the Student’s t test using Microsoft Office Excel or Kaplan 97. P<0.05 was considered significant.

Results

Notch Pathway Genes are Upregulated in Tissue Specimens of Patients with Rhabdomyosarcoma

We assessed the status of the Notch pathway in RMS by determining the expression of genes in the Notch pathway; we performed real-time PCR to determine the expression of these genes in normal human skeletal muscle specimen and 2 human eRMS specimens. RMS1 and RMS2 showed strong expression of Notch receptors NOTCH1, NOTCH3, and NOTCH4 in RMS specimens. Additionally, Notch ligands JAG1 and DLL1, target genes HEY1 and HES1, and transcription factor RBPJ were significantly upregulated in RMS (Fig. 1). Further, we showed that Notch pathway molecules are upregulated in RMS cell lines (Fig. S1). These findings suggest that the Notch pathway is activated in human RMS.

Figure 1
Notch pathway molecules are overexpressed in rhabdomyosarcoma cells.

Downregulation of the Notch Pathway by GSI X Suppresses Rhabdomyosarcoma Cell Proliferation

To examine whether the Notch pathway contributes to RMS pathogenesis, we used GSI X and GSI XX which are potent inhibitor of Notch pathway. WST-1 assay revealed that the proliferation of RD and KYM-1 cells was inhibited by 10 µM GSI X (Fig. 2A). In addition, GSI XX prevented RD and KYM-1 proliferation (Fig. S2). We evaluated cell death by GSI X treatment. GSI X treatment did not promote the expression of cleaved PARP and formation of the apoptotic small bodies (Fig. S3). Furthermore, the Notch target gene HES1 mRNA was downregulated by 10 µM GSI X, in RD and KYM-1 cell lines (Fig. 2B). These findings suggest that Notch pathway inhibition by GSI X treatment prevents the proliferation of RMS cells in vitro.

Figure 2
Effects of GSI X on the proliferation of rhabdomyosarcoma cells.

RBPJ is Essential for the Growth of Rhabdomyosarcoma

GSIs inhibit not only the Notch pathway but also other pathways [26], [27], [28]. We examined the function of the Notch pathway in RMS cell proliferation by analyzing the function of RBPJ. Real-time PCR revealed that RBPJ was upregulated 2.1 to 4.8-fold in RMS cell lines (Fig. 3A). To evaluate the function of RBPJ in RMS, we knocked down RBPJ expression by using siRNA. Efficacy of RNAi was confirmed by real-time PCR and western blotting assay, which showed that RBPJ RNAi decreased the expression of RBPJ mRNA and protein levels (Fig. 3B). Furthermore, knockdown of RBPJ decreased the expression of Notch target gene HES1 mRNA in RD cells (Fig. 3B). RD cells transfected with RBPJ siRNA showed a significantly lower number of colonies in soft agar than those with control siRNA (Fig. 3C). In addition to loss-of-function of RBPJ, we examined the effects of forced expression of RBPJ in RMS cells. Forced expression of RBPJ increased the expression of downstream target gene HES1 (Fig. 4A). The colony formation assay showed that forced expression of RBPJ led to formation of a greater number of colonies in soft agar than those with control vector (Fig. 4B). These findings show that RBPJ promotes the growth of human RMS cells in vitro.

Figure 3
Knockdown of RBPJ suppresses anchorage-independent growth of rhabdomyosarcoma cells. A,
Figure 4
Overexpression of RBPJ promotes rhabdomyosarcoma cell growth. A,

Knockdown of RBPJ Prevents the Growth of Rhabdomyosarcoma in vivo

We next investigated whether knockdown of RBPJ affects the growth of RMS cells in vivo. Knockdown of RBPJ by transfection of RBPJ shRNA significantly inhibited the growth of RD xenograft in nude mice as compared to that of control shRNA-transfected xenograft (Fig. 5A). Kaplan–Meier analysis revealed that knockdown of RBPJ showed a statistically significant improvement in the survival of mice (Fig. 5B). To examine whether RBPJ knockdown reduced cell proliferation in vivo, we examined the expression of Ki67 and cell cycle-related genes. The number of Ki67-positive cells in RBPJ shRNA-transfected xenograft was significantly lower than in control shRNA-transfected xenograft (Fig. 5C). Additionally, real-time PCR showed that the expression of the cell cycle accelerators, such as Cyclin D, Cyclin E, E2F1, and SKP2 was decreased in RBPJ shRNA-transfected xenograft. In contrast, the expression of p21, a negative regulator of cell cycle, was increased in RBPJ shRNA-transfected xenograft (Fig. 5C). These findings suggest that RBPJ plays a critical role in the growth of RMS by regulation of the cell cycle in vivo.

Figure 5
Knockdown of RBPJ inhibits the growth of rhabdomyosarcoma in nude mice. A,

Discussion

The Notch pathway is involved in several cellular processes such as proliferation, differentiation, apoptosis, cell fate decision, and maintenance of stem cells [8], [12], [29]. The Notch pathway plays a role in many cancers [19], [30], [31], [32].

Our findings revealed that Notch pathway molecules were upregulated in clinical samples of eRMS were consistent with those reported in previous studies. Kuroda, K. et al. showed that activation of the NOTCH1-RBPJ pathway via the DLL1 ligand was important for myogenic differentiation [33], [34]. We also found that the mRNA expression of NOTCH1, DLL1, and RBPJ is higher in eRMS specimens than in normal skeletal muscle specimens. Thus, the pathogenesis of RMS might be associated with the dysregulated activation of myogenic differentiation.

Recently, the Notch pathway has been reported to be highly active in human RMS [35], [36]. Roma J et al. reported that inhibition of the Notch pathway by GSIs reduced the invasiveness and metastasis of RMS in vitro [35]. In addition, Belyea et al. reported that Notch pathway inhibition by GSI and RNAi of NOTCH1 or HEY1 blocked RMS tumorigenesis [36]. GSIs, which were originally used in Alzheimer’s disease [37], are currently undergoing clinical trials for the treatment of several tumors [38], [39]. However, previous studies have shown that GSIs can kill breast cancer cells because of their nonspecific effect through their ability to inhibit the proteasome rather than blocking γ-secretase activity [25]. Additionally, GSIs proteolyze not only Notch receptor but also around 51 membrane proteins, including E-cadherin, VEGFR, and CXCL16 [40]. Furthermore, HEY1 is involved in TGF-β pathway [41]. Thus, therapeutic strategies including treatment with GSIs or those targeting HEY1 may affect other pathways. On the other hand, RBPJ acts only downstream of the Notch pathway, and nothing is known about its function in other pathways. Thus, we focused on the role of RBPJ to examine the bona fide function of the Notch pathway transcription factor in RMS tumorigenesis. The loss-of-function and gain-of-function of RBPJ indicated that RBPJ controled RMS cell growth in vitro. Although GSI treatment decreased the proliferation of RMS cells, knockdown of RBPJ did not decrease the proliferation in normal culture condition (data not shown). These findings suggest that GSI inhibit Notch pathway more intensively than RBPJ knockdown or might affect not only Notch pathway but also other signaling pathways. On the other hand, knockdown of RBPJ prevented RMS proliferation in soft agar (3D culture) and in vivo. In addition, knockdown of RBPJ caused significantly improved the survival of mice. These findings suggest that transcription of RBPJ activated by Notch pathway is essential for RMS proliferation in physiological conditions. Although these three studies inhibit Notch signaling by inhibitor or knockdown of different genes, all studies provide independent support for the idea that Notch pathway plays essential roles in RMS progression. Furthermore, Notch pathway plays essential roles in many cancers [19], [30], [31], [32]. Our results show that direct inhibition of RBPJ may offer a novel approach for inhibition of the Notch pathway not only in RMS but also in many cancers.

We showed that knockdown of RBPJ suppressed the expression of Cyclin D, Cyclin E, E2F1, and SKP2, whereas the expression of p21 increased in RBPJ shRNA-transfected xenograft. SKP2, a subunit of the ubiquitin-ligase complex SCFSKP2, is necessary for the degradation of p21 at the G1/S transition and during S phase in the cell cycle [42]. p21 inhibits CDK4-Cyclin D and thus suppresses the phosphorylation of RB and the sequestration of E2F1 and Cyclin E [43]. Therefore, our findings suggest that the inhibition of RBPJ prevents RMS growth in vivo by regulation of G1/S transition of the cell cycle.

Several studies have shown the relation between the Notch pathway and tumor-initiating cells (TICs) [44], and Sullivan et al. reported that aldehyde dehydrogenase (ALDH) activity selected for lung TICs is dependent on the Notch pathway [45]. Thus, we confirmed ALDH activity for the Notch pathway in RMS cell lines. However, no significant difference was observed in ALDH-positive population between RBPJ shRNA- and control shRNA-transfected RD cells (data not shown). Previously, we reported that the RMS cell lines included fibroblast growth factor receptor 3 (FGFR3)-positive TICs, which have high tumorigenic potential in vivo [46]. Hence, we examined the expression of FGFR3 in RBPJ shRNA- or control shRNA-transfected RD; however, no significant difference was observed in FGFR3-positive population in these cell lines (data not shown). These findings suggest that RBPJ does not have the roles in maintenance of ALDH or FGFR3-positive TICs in RMS cell lines. Recently, it has been reported that RMS cells contains a CD133-positive TICs [47], [48]. Thus, further studies to explore that the relation between the Notch pathway and CD133-positive RMS TICs are needed to elucidate the pathogenesis of RMS.

Major advances have been made for understanding the interactions between the Notch pathway and other pathways during carcinogenesis [6], [7]. Schreck et al. reported that the Notch target HES1 directly modulated GLI1, transcription factor of the Hedgehog pathway, in glioblastoma cells [49]. Additionally, we showed that the Hedgehog pathway was activated in human RMS [23]. Targeting both the Notch pathway and the Hedgehog pathway simultaneously may be more effective in eliminating RMS cells.

In conclusion, we revealed that the Notch pathway is functionally activated in RMS. Our findings show that inhibition of RBPJ prevents the growth of RMS in vitro and in vivo. These novel findings improve the understanding of the pathogenesis of RMS and suggest that RBPJ may be an attractive therapeutic target for patients with RMS.

Supporting Information

Figure S1

Notch pathway molecules are overexpressed in rhabdomyosarcoma cell lines. Expression of Notch pathway genes (receptors NOTCH1-4, ligands JAG1 and DLL1, target genes HES1, and HEY1) were assessed by real-time PCR in a human skeletal muscle cell line (HSkMC) and 3 human RMS cell lines. The Ct values of all RMS samples were normalized to those of ACTB. The values of the human RMS specimens were compared with those of the human skeletal muscle sample, which is defined as a relative expression of 1.0. Columns, mean values of 3 independent experiments. Bar, SD. *p<0.05, **p<0.01.

(TIF)

Figure S2

GSI XX prevents proliferation of rhabdomyosarcoma cells. RD and KYM-1 cells were treated with GSI XX or equal volume of DMSO vehicle. GSI XX treatment prevented the RMS proliferation.

(TIF)

Figure S3

GSI X treatment did not promote rhabdomyosarcoma cell apoptotic cell death. A, PARP and cleaved PARP protein levels in RD and KYM-1 cells were examine following 10 µM GSI X or equal volume of DMSO vehicle treatment. We used the PARP antibody which detect both full length PARP and cleaved PARP. Western blotting analysis revealed that GSI X treatment did not increase the expression of cleaved PARP. B, RD and KYM-1 cells were stained with Hoechst 33342 dye following 10 µM GSI X or equal volume of DMSO vehicle treatment. Apoptotic small body was not increased by GSI X treatment. Scale bar is 100 µm.

(TIF)

Acknowledgments

We are grateful to Hui Gao for the excellent technical assistance. We wish to thank the Joint-research laboratory of Kagoshima University Graduate School of Medical and Dental Sciences.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by Grants-in-Aid for Scientific Research (KAKENHI) (C) 19591725, (C) 20591786, (C) 21591919, (C) 21591920, (C) 22591663, (C) 24592238 and (C)23592195 and a Grant-in-Aid from the Ministry of Health, Labour, and Welfare of Japan for the Third Term Comprehensive Control Research for Cancer, and Scientific Research on Priority Areas 201201976 to HN from the Grant-in-Aid for JSPS Fellow. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Wachtel M, Schafer BW. Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev. 2010;36:318–327. [PubMed]
2. Rodeberg D, Paidas C. Childhood rhabdomyosarcoma. Semin Pediatr Surg. 2006;15:57–62. [PubMed]
3. Wachtel M, Schafer BW. Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev. 2010;36:318–327. [PubMed]
4. Gupta AA, Anderson JR, Pappo AS, Spunt SL, Dasgupta R, et al. Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: A Report From the Children’s Oncology Group Soft Tissue Sarcoma Committee. Cancer. 2011;118:1130–1137. [PubMed]
5. Perez EA, Kassira N, Cheung MC, Koniaris LG, Neville HL, et al. Rhabdomyosarcoma in Children: A SEER Population Based Study. J Surg Res. 2011;170:e243–e251. [PubMed]
6. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer. 2011;11:338–351. [PubMed]
7. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood. 2006;107:2223–2233. [PubMed]
8. Fiuza UM, Arias AM. Cell and molecular biology of Notch. J Endocrinol. 2007;194:459–474. [PubMed]
9. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7:678–689. [PubMed]
10. Gordon WR, Arnett KL, Blacklow SC. The molecular logic of Notch signaling–a structural and biochemical perspective. J Cell Sci. 2008;121:3109–3119. [PMC free article] [PubMed]
11. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137:216–233. [PMC free article] [PubMed]
12. Allenspach EJ, Maillard I, Aster JC, Pear WS. Notch signaling in cancer. Cancer Biol Ther. 2002;1:466–476. [PubMed]
13. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer. 2003;3:756–767. [PubMed]
14. Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene. 2003;22:6598–6608. [PubMed]
15. Hsieh JJ, Henkel T, Salmon P, Robey E, Peterson MG, et al. Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol Cell Biol. 1996;16:952–959. [PMC free article] [PubMed]
16. Strobl LJ, Hofelmayr H, Stein C, Marschall G, Brielmeier M, et al. Both Epstein-Barr viral nuclear antigen 2 (EBNA2) and activated Notch1 transactivate genes by interacting with the cellular protein RBP-J kappa. Immunobiology. 1997;198:299–306. [PubMed]
17. Aster JC, Blacklow SC, Pear WS. Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol. 2010;223:262–273. [PMC free article] [PubMed]
18. Sivasankaran B, Degen M, Ghaffari A, Hegi ME, Hamou MF, et al. Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res. 2009;69:458–465. [PubMed]
19. Tanaka M, Setoguchi T, Hirotsu M, Gao H, Sasaki H, et al. Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer. 2009;100:1957–1965. [PMC free article] [PubMed]
20. Matsunoshita Y, Ijiri K, Ishidou Y, Nagano S, Yamamoto T, et al. Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1. PLoS One. 2011;6:e16234. [PMC free article] [PubMed]
21. Kunigou O, Nagao H, Kawabata N, Ishidou Y, Nagano S, et al. Role of GOLPH3 and GOLPH3L in the proliferation of human rhabdomyosarcoma. Oncol Rep. 2011;26:1337–1342. [PubMed]
22. Nagao H, Ijiri K, Hirotsu M, Ishidou Y, Yamamoto T, et al. Role of GLI2 in the growth of human osteosarcoma. J Pathol. 2011;224:169–179. [PubMed]
23. Kawabata N, Ijiri K, Ishidou Y, Yamamoto T, Nagao H, et al. Pharmacological inhibition of the Hedgehog pathway prevents human rhabdomyosarcoma cell growth. Int J Oncol. 2011;39:899–906. [PubMed]
24. Sasaki H, Setoguchi T, Matsunoshita Y, Gao H, Hirotsu M, et al. The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth. Oncol Rep. 2010;23:677–684. [PubMed]
25. Han J, Ma I, Hendzel MJ, Allalunis-Turner J. The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition. Breast Cancer Res. 2009;11:R57. [PMC free article] [PubMed]
26. Ni CY, Murphy MP, Golde TE, Carpenter G. gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science. 2001;294:2179–2181. [PubMed]
27. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, et al. A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. Embo J. 2002;21:1948–1956. [PMC free article] [PubMed]
28. Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, et al. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol. 2000;2:428–434. [PubMed]
29. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–776. [PubMed]
30. Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, et al. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res. 2009;15:2291–2301. [PMC free article] [PubMed]
31. Stylianou S, Clarke RB, Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res. 2006;66:1517–1525. [PubMed]
32. Serafin V, Persano L, Moserle L, Esposito G, Ghisi M, et al. Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol. 2011;224:448–460. [PubMed]
33. Kuroda K, Tani S, Tamura K, Minoguchi S, Kurooka H, et al. Delta-induced Notch signaling mediated by RBP-J inhibits MyoD expression and myogenesis. J Biol Chem. 1999;274:7238–7244. [PubMed]
34. Hirsinger E, Malapert P, Dubrulle J, Delfini MC, Duprez D, et al. Notch signalling acts in postmitotic avian myogenic cells to control MyoD activation. Development. 2001;128:107–116. [PubMed]
35. Roma J, Masia A, Reventos J, Sanchez de Toledo J, Gallego S. Notch pathway inhibition significantly reduces rhabdomyosarcoma invasiveness and mobility in vitro. Clin Cancer Res. 2011;17:505–513. [PubMed]
36. Belyea BC, Naini S, Bentley RC, Linardic CM. Inhibition of the Notch-Hey1 Axis Blocks Embryonal Rhabdomyosarcoma Tumorigenesis. Clin Cancer Res. 2011;17:7324–7336. [PMC free article] [PubMed]
37. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006;66:602–604. [PubMed]
38. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005;435:959–963. [PubMed]
39. Tohda S, Sato T, Kogoshi H, Fu L, Sakano S, et al. Establishment of a novel B-cell lymphoma cell line with suppressed growth by gamma-secretase inhibitors. Leuk Res. 2006;30:1385–1390. [PubMed]
40. Beel AJ, Sanders CR. Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol Life Sci. 2008;65:1311–1334. [PMC free article] [PubMed]
41. Zavadil J, Cermak L, Soto-Nieves N, Bottinger EP. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. Embo J. 2004;23:1155–1165. [PMC free article] [PubMed]
42. Sarmento LM, Huang H, Limon A, Gordon W, Fernandes J, et al. Notch1 modulates timing of G1-S progression by inducing SKP2 transcription and p27 Kip1 degradation. J Exp Med. 2005;202:157–168. [PMC free article] [PubMed]
43. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400–414. [PMC free article] [PubMed]
44. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, et al. Targeting Notch to target cancer stem cells. Clin Cancer Res. 2010;16:3141–3152. [PMC free article] [PubMed]
45. Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 2010;70:9937–9948. [PMC free article] [PubMed]
46. Hirotsu M, Setoguchi T, Matsunoshita Y, Sasaki H, Nagao H, et al. Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells. Br J Cancer. 2009;101:2030–2037. [PMC free article] [PubMed]
47. Sana J, Zambo I, Skoda J, Neradil J, Chlapek P, et al. CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell lines. Anal Cell Pathol. 2011;34:1–16. [PubMed]
48. Walter D, Satheesha S, Albrecht P, Bornhauser BC, D’Alessandro V, et al. CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One. 2011;6:e19506. [PMC free article] [PubMed]
49. Schreck KC, Taylor P, Marchionni L, Gopalakrishnan V, Bar EE, et al. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res. 2010;16:6060–6070. [PMC free article] [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...